How do you make an anti-idiotype antibody that only sees your drug?
Why anti-idiotype antibodies are hard to buy and easy to get wrong
An anti-idiotype reagent has one job: to see your molecule and nothing else in a matrix full of endogenous human IgG. That is an unusually demanding specificity requirement, and it is the reason a generic anti-human-IgG reagent will not do. The failure mode is quiet — an assay that appears to work in buffer and drifts in serum, because the reagent was never forced to discriminate against the background it will meet.
The second thing that goes wrong is format. Teams often order “an anti-idiotype antibody” and discover mid-validation that they needed the version that binds only the drug–antigen complex, or only free drug, and that the reagent they have cannot make that distinction. The format has to be specified before selection, because it changes how the panning is run.
The formats we deliver
| Format | What it binds | Typical use |
|---|---|---|
| Free-drug-specific | Drug that is not engaged with antigen | Free-drug PK; target engagement |
| Complex-only (type 3) | Only the drug–antigen complex | Bound-drug PK; confirming engagement in vivo |
| Drug-capture (total drug) | Drug regardless of antigen occupancy | Total-drug PK; bridging ADA assays |
We have a deep track record across all of these, including the type-3 complex-only format that is the hardest of the three to obtain.
How we do it
We raise antibodies against the idiotype of your drug and pan on the drug while subtracting on irrelevant IgG, so clones that recognise framework or constant regions are removed during selection rather than filtered out afterwards. The starting repertoire is rabbit, selected by phage display — which matters here for a specific reason: rabbits mount strong responses against human IgG idiotypes that mice, being immunologically closer in some frameworks, often do not, and the selection step lets us apply the discrimination pressure that defines the reagent.
Where the assay needs free-versus-complex discrimination, that condition is built into the panning: clones are selected in the presence and absence of antigen so that the discrimination is a property they were chosen for rather than one we hope they have.
- Idiotype-specific clones in the format you specified, with sequences
- Free versus complex discrimination data
- Specificity data against irrelevant human IgG
- Recombinant material, so the reagent is reproducible for the life of the programme rather than lot-limited
Recombinant supply matters more than it sounds for an anti-idiotype. These reagents sit inside a validated bioanalytical method, sometimes for a decade. A hybridoma that drifts or a stock that runs out forces revalidation; a sequence does not.
Need an anti-idiotype for a regulated assay?
Tell us the drug, the format you need, and the matrix it has to work in. A PhD scientist reads it and replies within two business days. No NDA needed to start.
Talk to a scientist →Frequently asked questions
How much drug do you need to start?
Milligram quantities are typically sufficient for immunization and selection. Tell us what you have available and we will scope around it rather than the other way round.
Can you generate an anti-idiotype against a bispecific or a fragment?
Yes. Bispecifics raise an extra question — whether you need a reagent specific to one arm, to the other, or to the assembled molecule — and that choice should be made before selection because it determines the subtraction strategy.
Will the reagent work in serum or plasma?
That is exactly what the subtraction against irrelevant IgG is for. If your matrix has particular features — high drug concentrations, a soluble antigen sink, an unusual species — say so at scoping so the selection reflects it.
Can you also supply a positive-control anti-drug antibody?
Yes. Surrogate positive controls for ADA assays are the same class of problem and are commonly run alongside the anti-idiotype campaign.
Do we own the resulting clones?
Yes, sequences included, with no downstream royalties in standard scope. For a reagent that will live inside a regulated method for years, that ownership is usually the deciding factor.